Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
about
Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic micePrevalence of type 2 diabetes and its complications in India and economic costs to the nation.Transplantation of mesenchymal cells improves peripheral limb ischemia in diabetic rats.Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?Quercetin, a Lead Compound against Type 2 Diabetes Ameliorates Glucose Uptake via AMPK Pathway in Skeletal Muscle Cell Line.Changes of myocardial lipidomics profiling in a rat model of diabetic cardiomyopathy using UPLC/Q-TOF/MS analysis.Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats.C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.Stem cells in the diabetic infarcted heartDiabetes-related microvascular and macrovascular diseases in the physical therapy settingReversal of diabetic vasculopathy in a rat model of type 1 diabetes by opiorphin-related peptidesRhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular responseReduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.Type 2 diabetes restricts multipotency of mesenchymal stem cells and impairs their capacity to augment postischemic neovascularization in db/db mice.Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.Predictors and prevention of diabetic cardiomyopathy.Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.Diabetes and sexual dysfunction: current perspectives.Protective effects of physiological testosterone on advanced glycation end product‑induced injury in human endothelial cells.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study.Stem cells and diabetic cardiomyopathy: from pathology to therapy.Role of Moesin in Advanced Glycation End Products-Induced Angiogenesis of Human Umbilical Vein Endothelial Cells.Potential regulatory mechanisms of lncRNA in diabetes and its complications.Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?Phytoestrogen calycosin-7-O-β-D-glucopyranoside ameliorates advanced glycation end products-induced HUVEC damage.Improving the Pharmacokinetics of GPR40/FFA1 Full AgonistsEffect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?Features analysis of lower extremity arterial lesions in 162 diabetes patients.High glucose attenuates VEGF expression in rat multipotent adult progenitor cells in association with inhibition of JAK2/STAT3 signalling.Peroxynitrite-induced nitration of cyclooxygenase-2 and inducible nitric oxide synthase promotes their binding in diabetic angiopathySitagliptin-mediated preservation of endothelial progenitor cell function via augmenting autophagy enhances ischaemic angiogenesis in diabetes.Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study.Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.Extracellular Vesicles as Protagonists of Diabetic Cardiovascular Pathology.Protective effect of angiotensin-(1-7) against hyperglycaemia-induced injury in H9c2 cardiomyoblast cells via the PI3K̸Akt signaling pathway.ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability.Advanced glycation end products impair K(Ca)3.1- and K(Ca)2.3-mediated vasodilatation via oxidative stress in rat mesenteric arteries.
P2860
Q27317653-3C51B239-1746-414F-84AE-13606837415DQ30234746-C9709687-B796-4D20-8145-F4D636873A28Q30751275-B84B692A-8479-4A0C-9467-D180DC8CCB28Q33654306-A7CE4166-AE0C-46F6-9C51-2D6A4B5A9F20Q33774651-89A1572C-516A-4E8E-BA42-FDE8E803C531Q33921629-D0D796B7-F182-441B-934B-94E411EB9447Q34591116-AB2AF601-5E0C-4BC6-A9B0-BE28F90BBF7DQ34699045-2A6680F2-C4C3-4720-BEA2-BB8B350374D1Q34773408-20AD13DE-DA73-401E-A472-00A8F5AF7956Q34830905-FECC809C-B762-45E8-A448-539D921427CCQ35395573-8291DEF3-97AD-405F-AAA6-D9F1D03EC187Q35759021-ECE9BB8F-D8C3-49AC-B14E-0AA9F157F214Q35859307-1E0EAA47-2328-4395-A9C1-2BCD95AD9737Q36519821-7D6C5296-E2E8-4A13-A0B8-9729496BFD29Q36522638-F85BF114-216B-4E72-BCA3-60BF2533DFC2Q36765350-2BBFE450-F28E-4ED7-9CED-CDE73AE6DC22Q36776922-37743B38-DB2B-4073-B4BB-15088455CE31Q37106937-86DB1DF1-7E3A-4258-A907-004356CFBC49Q37139427-240141BB-CDE6-41B4-ACEF-1431FB4710EBQ37630425-B1AD56C9-AB67-4CD9-9F31-309E0099009AQ37722123-8537F1AA-AF71-4678-A32A-3D95C523B7E4Q38200957-7ED97A5F-355F-4035-A8B3-9ACE714B2C04Q38753187-39EFD861-2318-4888-9650-19737C4EB77FQ38843402-505A3D46-E536-4820-ABBF-179E2C492BDCQ38858414-2B77FBBE-19B6-4547-B734-53F44166681AQ39126178-62BF3CFE-04D6-441A-9651-02D3CF313195Q39451162-8248EAB0-BC28-4728-9CE0-091136EAB5C9Q39529329-E21BE31B-79EB-4447-A8BF-B4919FBB5CAEQ39782891-557A1C6B-A9D8-4F29-BD1A-854467F438C3Q40541424-F12C46A9-B7AD-4270-AA1A-675BE64A40AAQ40643042-ACFF4CC5-56D0-43D7-9AD0-BDF59D699CACQ41966597-6F10F3D5-43C8-47B5-84A5-B7A1569C8E43Q42429604-4A0056A6-D1B7-41B2-B004-3540C5BA11E8Q42513552-CBCC189F-4EC1-44E7-A2A1-DA18CD67822AQ46230278-1E3474C5-2729-4EFE-B55D-2CCFD013A7CFQ46958950-2B1A55AA-5766-4D04-BAE3-FBE2C40ECE7CQ47138160-DE418C6D-152D-4B9F-9D58-3FB234FB58D1Q47246750-D5C52A4D-CEFF-4F24-9E73-2121AECC63A4Q47938284-8C245ABA-410A-4225-95F4-C6EBC723343DQ47966996-4039A222-A531-46AD-8F4F-8E4BF6F63E5D
P2860
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
@en
type
label
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
@en
prefLabel
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
@en
P2093
P2860
P1476
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis.
@en
P2093
Abdul Rahman A Rashid
Aziz Al-Shafi Ismail
Sayeeda Rahman
Tahminur Rahman
P2860
P304
P356
10.1111/J.1463-1326.2006.00655.X
P577
2007-11-01T00:00:00Z